open access

Vol 14, No 6 (2018)
Review paper
Published online: 2019-03-15
Get Citation

Gastrointestinal stromal tumours (GIST) — 2018

Piotr Rutkowski, Anna Szumera-Ciećkiewicz
DOI: 10.5603/OCP.2018.0053
·
Oncol Clin Pract 2018;14(6):399-407.

open access

Vol 14, No 6 (2018)
REVIEW ARTICLES
Published online: 2019-03-15

Abstract

Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours of gastrointestinal tract. Advances in the understanding of the pathologic-molecular mechanisms of GIST pathogenesis have emerged GIST as a model of targeted therapy in oncology. The paper describes advances in diagnostics and therapy of these tumours based on new scientific basis. Radical surgery is still the mainstay treatment for primary, localized, resectable GISTs, although high percentages of the patients after potentially curative operations develop recurrent or metastatic disease; thus all GIST should be evaluated for potential adjuvant therapy with imatinib. In inoperable/metastatic lesions the treatment of choice is tyrosine kinase inhibitor — imatinib mesylate In case of disease progression the increase of imatinib dose to 800 mg daily is recommended and if further progression exists — sunitinib in the initial dose 50 mg daily should be introduced, thereafter sorafenib/regorafenib or clinical trial with new drugs (e.g. BLU-285 or DCC2618).

Abstract

Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours of gastrointestinal tract. Advances in the understanding of the pathologic-molecular mechanisms of GIST pathogenesis have emerged GIST as a model of targeted therapy in oncology. The paper describes advances in diagnostics and therapy of these tumours based on new scientific basis. Radical surgery is still the mainstay treatment for primary, localized, resectable GISTs, although high percentages of the patients after potentially curative operations develop recurrent or metastatic disease; thus all GIST should be evaluated for potential adjuvant therapy with imatinib. In inoperable/metastatic lesions the treatment of choice is tyrosine kinase inhibitor — imatinib mesylate In case of disease progression the increase of imatinib dose to 800 mg daily is recommended and if further progression exists — sunitinib in the initial dose 50 mg daily should be introduced, thereafter sorafenib/regorafenib or clinical trial with new drugs (e.g. BLU-285 or DCC2618).
Get Citation

Keywords

gastrointestinal stromal tumour; GIST; molecular diagnostics; imatinib; sunitinib; regorafenib; avapritinib; DCC2618

About this article
Title

Gastrointestinal stromal tumours (GIST) — 2018

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 6 (2018)

Article type

Review paper

Pages

399-407

Published online

2019-03-15

DOI

10.5603/OCP.2018.0053

Bibliographic record

Oncol Clin Pract 2018;14(6):399-407.

Keywords

gastrointestinal stromal tumour
GIST
molecular diagnostics
imatinib
sunitinib
regorafenib
avapritinib
DCC2618

Authors

Piotr Rutkowski
Anna Szumera-Ciećkiewicz

References (34)
  1. Steigen SE, Eide TJ. Trends in incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population of northern Norway. APMIS. 2006; 114(3): 192–200.
  2. Søreide K, Sandvik OM, Søreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016; 40: 39–46.
  3. Rutkowski P, Ługowska I, Fijuth J, et al. Soft tissue sarcomas in adults. Oncol Clin Pract 2017; 13: 181–201. DOI: 10 5603/OCP. ; 2017: 0025.
  4. Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med. 2009; 266(1): 43–52.
  5. Miettinen M, Wang ZF, Sarlomo-Rikala M, et al. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol. 2011; 35(11): 1712–1721.
  6. Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001; 438(1): 1–12.
  7. Levy AD, Remotti HE, Thompson WM, et al. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. Radiographics. 2003; 23(2): 283–304, 456; quiz 532.
  8. Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011; 104(8): 865–873.
  9. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006; 130(10): 1466–1478.
  10. Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006; 30(4): 477–489.
  11. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005; 29(1): 52–68.
  12. Rutkowski P. (red.). Mięsaki tkanek miękkich. Via Medica, Gdańsk 2015.
  13. Casali PG, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology. 2018.
  14. Rutkowski P, Wozniak A, Dębiec-Rychter M, et al. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection. Cancer. 2011; 117(21): 4916–4924.
  15. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012; 307(12): 1265–1272.
  16. Rutkowski P, Hompes D. Combined Therapy of Gastrointestinal Stromal Tumors. Surg Oncol Clin N Am. 2016; 25(4): 735–759.
  17. Joensuu H, Wardelmann E, Sihto H, et al. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017; 3(5): 602–609.
  18. Wang D, Zhang Q, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol. 2012; 19(4): 1074–1080.
  19. Rutkowski P, Gronchi A, Hohenberger P, et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol. 2013; 20(9): 2937–2943.
  20. Heinrich MC, Rankin C, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347(7): 472–480.
  21. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008; 26(4): 620–625.
  22. Rutkowski P, Andrzejuk J, Bylina E, et al. What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib? Med Oncol. 2013; 30(4): 765.
  23. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21(23): 4342–4349.
  24. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368(9544): 1329–1338.
  25. Reichardt P, Kang YK, Rutkowski P, et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 2015; 121(9): 1405–1413.
  26. Serrano C, George S. Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol. 2014; 6(3): 115–127.
  27. Demetri GD, Reichardt P, Kang YK, et al. GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381(9863): 295–302.
  28. Montemurro M, Gelderblom H, Bitz U, et al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. Eur J Cancer. 2013; 49(5): 1027–1031.
  29. Rutkowski P, Jagielska B, Andrzejuk J, et al. The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST). Contemp Oncol (Pozn). 2017; 21(4): 285–289.
  30. BLU-285, DCC-2618 Show Activity against GIST. Cancer Discov. 2017; 7(2): 121–122.
  31. Schneider-Stock R. BLU-285-the breakthrough in treatment of patients with aggressive systemic mastocytosis and gastrointestinal stromal tumor. Ann Transl Med. 2018; 6(11): 232.
  32. Du CY, Zhou Ye, Song C, et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. Eur J Cancer. 2014; 50(10): 1772–1778.
  33. Bauer S, Rutkowski P, Hohenberger P, et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol. 2014; 40(4): 412–419.
  34. Tielen R, Verhoef C, van Coevorden F, et al. Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? World J Surg Oncol. 2012; 10(2): 111–155.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl